Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.65)
# 2,018
Out of 5,182 analysts
52
Total ratings
41.3%
Success rate
6.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANE Veradermics | Initiates: Overweight | n/a | $68.80 | - | 1 | Mar 2, 2026 | |
| EVMN Evommune | Initiates: Overweight | n/a | $25.51 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Overweight | n/a | $519.61 | - | 5 | Nov 5, 2025 | |
| ATYR aTyr Pharma | Downgrades: Neutral | n/a | $0.83 | - | 2 | Sep 15, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $13.66 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $54.51 | +19.24% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $10.15 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $28.96 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $4.04 | - | 1 | Mar 18, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $11.21 | - | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $4.22 | +136.97% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.96 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $33.73 | -28.85% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.89 | +15,470.93% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $1.80 | +677.78% | 1 | Mar 3, 2021 |
Veradermics
Mar 2, 2026
Initiates: Overweight
Price Target: n/a
Current: $68.80
Upside: -
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: n/a
Current: $25.51
Upside: -
Madrigal Pharmaceuticals
Nov 5, 2025
Upgrades: Overweight
Price Target: n/a
Current: $519.61
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.83
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $13.66
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $54.51
Upside: +19.24%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.15
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $28.96
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.04
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $11.21
Upside: -
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $4.22
Upside: +136.97%
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.96
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $33.73
Upside: -28.85%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.89
Upside: +15,470.93%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $1.80
Upside: +677.78%